NCT06689540招募中1 期
First-in-human Clinical Study of Mts105 for Advanced Hepatocellular Carcinoma
Shen Lin1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2024年11月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Incidence of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs).
研究概览
简要总结
This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.
详细描述
MTS105 is an mRNA-LNP combination. Once the mRNA is delivered to the liver via lipid nanoparticles (LNP), it translates into a therapeutic bispecific T-cell engager designed to activate T cells to target and destroy liver cancer cells.
MTS105 is anticipated to offer liver-targeted delivery, specific binding to hepatocellular carcinoma cells, a broad therapeutic window, and potent anti-tumor effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as mixed hepato-cholangiocellular carcinoma;
- •Positive for GPC3 expression per immunohistochemical (IHC) staining.
- •Failure of standard systemic therapies, including at least one immune checkpoint inhibitor and one targeted therapy (Tyrosine Kinase Inhibitors, and/or anti vascular endothelial growth factor agent).
- •Presence of a measurable tumor lesion (per RECIST/ mRECIST criteria).
- •Barcelona Clinical Liver Cancer Stage B or C (BCLC B/C)
- •Child-Pugh Score ≤ 6
- •ECOG score ≤ 1
- •Adequate organ and bone marrow function as defined by the following laboratory criteria:
- •Hematology: No blood transfusion or colony-stimulating factor therapy within 7 days prior to the first dose. The following hematological parameters should be met:Absolute neutrophil count ≥ 1.5 × 10^9/L;Lymphocyte count ≥ 0.5 × 10^9/L;Hemoglobin ≥ 90 g/L;Platelet count ≥ 75 × 10^9/L;
- •Liver function:Total bilirubin ≤ 2.5 mg/dL;Albumin ≥ 28 g/L;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN;
- •International Normalized Ratio (INR) ≤ 2.3;Oral anticoagulant therapy at a stable dose for at least 2 weeks. If oral warfarin is used, the patient must have an INR ≤ 3.0 and no bleeding events within 28 days prior to administration;
- •Renal function:Serum creatinine ≤ 1.5 × ULN, or endogenous creatinine clearance ≥ 45 mL/min (as determined by the CKD-EPI formula);Urinary protein < 2+, or urinary protein ≥ 2+ but with 24-hour protein quantification ≤ 1.0 g
- •Cardiac function:Left ventricular ejection fraction (LVEF) ≥ 50%; No clinically significant abnormal ECG findings (chronic atrial fibrillation is allowed, provided it does not require medication);
- •Capable of full communication with the investigator, with the ability to understand and comply with study requirements, and able to understand and sign the informed consent form (ICF).
排除标准
- •Any known active intracranial metastases, or brain metastases that have been treated for less than 4 weeks.
- •Recent Antitumor Therapy:
- •Treatment with any immune checkpoint inhibitor within 4 weeks (28 days) prior to the first dose.
- •Received any investigational drug within 4 weeks prior to the first dose.
- •Received localized therapy for hepatocellular carcinoma (HCC), including but not limited to arterial chemoembolization (TACE), arterial infusion chemotherapy (HAIC), Y-90 radioembolization, ablative therapy, or stereotactic radiation therapy (SBRT), within 4 weeks prior to the first dose.
- •Received other anticancer therapies, such as multi-targeted tyrosine kinase inhibitors (mTKIs) and/or anti-VEGF therapies, within 3 weeks.
- •Received non-specific immunomodulatory therapy, including but not limited to interleukin, interferon, thymidine, etc., within 2 weeks prior to the first dose.
- •Received herbal or proprietary Chinese medicine for antitumor indications within 1 week prior to the first dose.
- •Previously received experimental treatment targeting GPC3 (patients may be enrolled if they remain positive for GPC3 upon testing).
- •History of liver transplantation or hematopoietic stem cell transplantation.
- •Unresolved toxicity from prior anticancer therapy (> grade 1, according to CTCAE v5.0).
- •Major surgery (other than biopsy) within 28 days prior to the first dose.
- •Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg).
- •Class III-IV heart failure by New York Heart Association (NYHA) criteria within 6 months prior to the first dose, unstable angina, myocardial infarction, bypass surgery, stent placement, cerebral infarction, or clinically significant valvular heart disease.
- •QTcF ≥ 450 ms in men and ≥ 470 ms in women (by Fridericia formula).
- •Severe infection within 4 weeks before the first dose (excluding viral hepatitis), or any signs or symptoms of active infection within 2 weeks before the first dose, or patients requiring antibiotic treatment within 2 weeks (excluding local medications and prophylactic antibiotics); unexplained fever > 38.5°C before the first dose.
- •For HBV-associated HCC:
- •HBsAg (+) : less than 2 weeks of HBV antiviral standard treatment before the first administration of study drug, with an HBV DNA viral load ≥ 1000 IU/mL.
- •HBcAb (+) , HBsAg (-): HBV DNA viral load ≥ 1000 IU/mL.
- •Hepatitis C virus-infected subjects who have not completed 4 weeks of antiviral treatment.
- •Positive for human immunodeficiency virus (HIV+).
- •Subjects requiring systemic corticosteroids (equivalent dose of prednisone > 10 mg/day) or other immunosuppressive drugs within 14 days prior to the first dose or during the study.
- •History of autoimmune disease requiring systemic treatment within 2 years prior to the first dose.
- •History of other malignancies within 2 years prior to the first dose (excluding cured skin basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ, breast ductal carcinoma in situ, or other cancers that the investigator believes are cured and have an extremely low risk of recurrence).
- •Women who are pregnant or breastfeeding.
- •Any other condition that, in the opinion of the investigator, makes participation in the study inappropriate.
研究组 & 干预措施
dose level #1
Experimental
Starting dose, 0.05 ug/kg
干预措施: MTS105 (Biological)
dose level #2
Experimental
dose escalation, 0.5 ug/kg
干预措施: MTS105 (Biological)
dose level #3
Experimental
dose escalation, 3.0 ug/kg
干预措施: MTS105 (Biological)
dose level #4
Experimental
dose escalation, 15.0 ug/kg
干预措施: MTS105 (Biological)
dose level #5
Experimental
dose escalation, 30.0 ug/kg
干预措施: MTS105 (Biological)
dose level #6
Experimental
dose escalation, 45.0 ug/kg
干预措施: MTS105 (Biological)
结局指标
主要结局
Incidence of treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs).
时间窗: From enrollment to the end of treatment at 4 weeks
Incidence of TEAEs,and SAEs.
Maximal Tolerance Dose (MTD)
时间窗: Within the first 28-days following first dose
Determined based on the occurrence of dose-limiting toxicity (DLT).
次要结局
- Peak Plasma Concentration (Cmax)(Within the first 28-days following first dose)
- Area under the plasma concentration versus time curve (AUC)(Within the first 28-days following first dose)
- Time for peak concentration (Tmax)(Within the first 28-days following first dose)
- Elimination half-life(Within the first 28-days following first dose)
- Steady-state concentration(Within the first 28-days following first dose)
- Objective Response Rate(through study completion, an average of 1 year)
- Duration of Response (DOR)(through study completion, an average of 1 year)
- Progression Free Survival (PFS)(through study completion, an average of 1 year)
- Overall Survival (OS)(through study completion, an average of 1 year)
研究者
Shen Lin
Professor
Peking University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)Peripheral Artery DiseaseFemoropopliteal Artery DiseaseNCT02145065Balton Sp.zo.o.66
已完成
1 期
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid TumorsSolid Tumor, AdultNCT05586321Genmab26
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy VolunteersParkinson's DiseaseNCT05844787Mthera Pharma Co., Ltd.48
招募中
1 期
A Study of DM005 in Patients With Advanced Solid TumorsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckSolid CarcinomaNCT06515990Doma Biopharmaceutical（Suzhou）Co., Ltd.208
已完成
1 期
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor MalignanciesOncologyMET Gene AmplificationMET Gene MutationNon Small Cell Lung CancerNSCLCNCT02648724Symphogen A/S57